Inositol phosphoglycan-mediated insulin signaling

Inositol phosphoglycan-mediated insulin signaling refers to a **cellular signal transduction mechanism** in which inositol-containing compounds, specifically inositol phosphoglycans (IPGs), act as **secondary messengers downstream of the insulin receptor**. When insulin binds its receptor, it triggers the release of IPGs from membrane-bound precursors via activation of enzymes such as phospholipase C. These IPGs—containing either myo-inositol or D-chiro-inositol—mediate several metabolic effects attributed to insulin, including stimulation of glucose uptake by GLUT4 transporters, promotion of glycogen synthesis, and modulation of oxidative glucose metabolism[1][2][3][4].\n\nBoth myo-inositol and D-chiro-inositol are essential for proper intracellular transmission of the metabolic signal initiated by insulin. Deficiencies or imbalances in these molecules have been linked to impaired glucose handling, increased risk for type 2 diabetes mellitus, polycystic ovary syndrome (PCOS), and other states characterized by **insulin resistance**[1][3]. Clinical studies suggest that supplementation with these inositols can improve glycemic control and reduce hyperinsulinemia[3].\n\nThis entry is not a single molecular target such as a receptor or enzyme but rather describes an entire **signaling pathway involving multiple molecular components**, including small molecule mediators. Therefore, it is not considered a canonical therapeutic target itself but represents an important biological process relevant to drug development for metabolic diseases.\n\nKey points:\n\n> \"Insulin uses inositol phosphoglycans (IPGs) as secondary messengers... controlling oxidative/nonoxidative metabolisms of glucose as well as uptake by GLUT4\"[1]\n\n> \"D-Chiro-Inositiols are incorporated into the IPG... involved in insulin signal transduction; defective D-Chiro-Inositiols may be a major contributor to insulin resistance\"[2]\n\n> \"Myo-ins has become a reliable treatment option... for PCOS patients with insulin resistance\"[3]\n\nBecause this term refers to a mechanism/pathway rather than an individual protein or gene product typically targeted by drugs, it should not be classified strictly as a therapeutic target.\n\nIf you need information on specific proteins within this pathway—such as the *insulin receptor*, *phosphoinositide-specific phospholipase C*, or *GLUT4*—please specify so structured data can be provided at that level.

Other names

Inositol phosphoglycan signalingIPG-mediated insulin signalingMyo-inositol/D-chiro-inositol secondary messenger pathway (contextual)